Osteobolin-C™ Frequently Asked Questions
- 02-07-2007, 07:09 PM
Osteobolin-C™ Frequently Asked Questions
Q: When is the best time to take Osteobolin-C?
A: Take first dose with breakfast, and second dose with dinner. It can be taken with or without food.
Q: How long will it take to feel the positive benefits of Osteobolin-C?
A: If taken at the recommended dosage, you should feel some reduction of joint and tendon pain within a few days. In order to experience the full healing and repair effects of the compound, 2-3 weeks of usage is often necessary. Long term users report minimal if any reoccurring pain in the effected areas.
Q: What makes Osteobolin-C different than other bone and joint health products?
A: Glucosamine and chondroitin have been scientifically proven to aide in muscle and tissue repair, but take months for any effect to be noticed. Furthermore, only about half of the users experience any improvement at all, and it is very expensive. Osteobolin-C employs a completely different approach. Cissus quadrangularis is the active ingredient in Osteobolin-C, unique compound with many beneficial properties. It has been shown to effectively block the destructive hormone cortisol, plus promote new tissue cell growth at the point of injury or inflammation. It also displays potent anti-inflammatory properties as well..
Q: Has there been any scientific research on the healing potential of Osteobolin-C?
A: Our research shows that the use of Osteobolin-C on bone fractures can increase the healing process 30% faster that any other product available on the market. Cissus Quadrangularis is an ingredient used in ancient Chinese medicines and one of our main ingredients. It has been proven to have great healing qualities in the mineralization of bone. There is also ample empirical and anecdotal evidence of its positive healing effects on cartilage, tendon, and skeletal muscle.
Q: Is it safe to use Osteobolin-C for long periods of time, or should I cycle it?
A: Osteobolin-C is very safe and can be taken continuously for both new and old injuries. It also serves as a great preventative supplement, as it helps keep connective tissue healthy and less prone to injury.
Q: How does Osteobolin-C limit the inflammatory process?
A: Osteobolin-C minimizes myeloperoxidase activity. This is a process where enzymes are released to at the site of an injury which produce hypochlorous acid, which is toxic to cells. Myeloperoxidase can be considered a double-edged sword, in that while it kills bacteria and pathogens associated with the inflammatory process, it also kills healthy cells which are necessary for healing. By inhibiting this process, Osteobolin-C can attenuate pain and swelling associated with bone, tendon, and ligament damage, which allows for faster healing and a quicker time to recovery.
Q: Because of the above, will Osteobolin-C reduce my ability to fight infection?
A: Absolutely not. Cissus quadrangularis also has antibacterial and antimicrobial properties that far outweigh any loss of resistance to infection due to myeloperoxidase inhibition.
Q:Why is vitamin C necessary in the formula?
A: Vitamin C is an important part of the Osteobolin-C formula, because it converts proline to hydroxyproline, the main substance needed for the formation of collagen which is what aids in the natural development of tissue remodeling.
Q: Who can benefit from taking Osteobolin-C?
A: This product is useful for any male or female over the age of 18 and who is had or currently has bone, tendon, or joint issues. It also can safely be used by anyone who is simply looking to maintain good connective tissue health. Virtually everyone can benefit from this product.
Q: What supplements do you recommend while taking Osteobolin-C to maximize results?
A: We recommend whey protein supplementation, with a goal of attaining 1-1.5 grams of protein per day per pound of bodyweight. Additionally, we strongly encourage the use of an essential fatty acid product with omega 3/6/9 and a good multivitamin with minerals.toes-on-the-nose.blogspot.com Deployed blogging
- 02-12-2007, 12:29 AM
What is the ingredient profile per capsule? It is sort of confusing as the weight dependant dosage schedule makes it easy to manage dosage but a little difficult to assess actual mg dosage. I'm assuming 300mg per cap?
- 02-12-2007, 08:56 AM
I believe the labels states "Amount Per Capsule". let me double check............Applied Nutriceuticals Representative
Better Results Through Science
Success occurs when everything you have is APPLIED.
Have you heard about N.O. Uptake? ;-)
02-12-2007, 09:21 AM
02-12-2007, 07:13 PM
02-13-2007, 02:04 AM
Even with my (near) blown rotator cuff, this stuff is helping me repair. What has worked best for me is to take it about 20 minutes before the gym, especially before chest day.
02-13-2007, 09:17 AM
05-28-2007, 11:22 PM
05-30-2007, 05:12 PM
Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease.
Respirology. 2003 Sep;8(3):316-20.
The proteolytic enzyme serrapeptase is widely used in clinical practice in Japan. We investigated the effect of serrapeptase on sputum properties and symptoms in patients with chronic airway diseases. This study was an open-labeled trial with a non-treatment control group. Patients were randomly assigned to oral treatment and without serrapeptase 30 mg/day for 4 weeks. Patients collected sputum samples for about 4 hours in the morning on the day the trial began and 4 weeks later. Part of each sputum sample was weighed and then completely dried and reweighed. The percentage solid component, viscosity and elasticity of the sputum were measured. Mucociliary transportability index was measured using ciliated bovine trachea ex vivo. After 4 weeks of serrapeptase treatment, sputum weight in the morning, percentage solid component, viscosity and elasticity of sputum, sputum neutrophil count, frequency of coughing and frequency of expectoration significantly decreased. CONCLUSIONS: serrapeptase may exert a beneficial effect on mucus clearance by reducing neutrophil numbers and altering the viscoelasticity of sputum in patients with chronic airway diseases.
A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome.
J Assoc Physicians India. 1999 Dec;47(12):1170-2.
This study was planned to assess the response of serratiopeptidase ( serrapeptase ) in patients with carpal tunnel syndrome (CTS). Twenty patients with CTS were evaluated clinically. After baseline electrophysiological studies, these patients were given serrapeptase 10 mg twice daily with initial short course of nimesulide. Clinical and electrophysiological reassessment was done after 6 weeks. RESULTS: Sixty five percent of serrapeptase cases showed significant clinical improvement which was supported by improvement in electrophysiological parameters. Recurrence was reported in four cases. No significant side effect was observed. CONCLUSIONS: Serrapeptase therapy may proved to be a useful alternative mode of conservative treatment. Larger study may be further helpful to establish the role of serrapeptase in CTS. Serratiopeptidase therapy.
Intestinal absorption of serrapeptase in rats.
Biotechnol Appl Biochem. 1994 Aug;20 ( Pt 1):101-8.
A sensitive sandwich enzyme immunoassay for serrapeptase, an orally available anti-inflammatory proteinase, was established using affinity-purified anti-serrapeptase rabbit IgG and its Fab' fragment conjugated with horseradish peroxidase as the first and the second antibodies respectively. Serrapeptase in the plasma was determined after its oral administration (100 mg/kg) to rats. The peak concentration was observed between 30 min and 2 h after administration. These results indicate that orally administered serrapeptase was absorbed from the intestinal tract and transferred into the circulation in an enzymically active form.
Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo.
University of Naples, Italy.
J Int Med Res. 1990 Sep-Oct;18(5):379-88.
The efficacy and tolerability of serrapeptase were evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects suffering from acute or chronic ear, nose or throat disorders. Treatment lasted 7-8 days, with the drug or placebo being administered at a rate of two tablets three times a day. After 3-4 days' treatment, significant symptom regression was observed in serrapeptase treated patients. There was also a significant reduction in symptoms after 7-8 days for patients in both treatment groups but the response was more marked in those patients receiving the active drug. Statistical comparison between the two groups confirmed the greater efficacy and rapid action of the serrapeptase against all the symptoms examined at both stages. Tolerance was found to be very good and similar for both groups. It is concluded that serrapeptase has anti-inflammatory, anti-edemic and fibrinolytic activity and acts rapidly on localized inflammation. Serratiopeptidase is anti-inflammatory.
A case of pneumonitis due to serrapeptase
Nihon Kyobu Shikkan Gakkai Zasshi. 1989 Oct;27(10):1231-6.
A case of pneumonitis due to Serrapeptase was described. A 69-year-old man was treated with Serrapeptase for 16 days because of common cold, then fever, nonproductive cough and dyspnea developed and chest X-ray revealed diffuse fine granular shadows in bilateral lung fields. Once the administration of Serrapeptase was halted, symptoms, chest X-ray abnormalities and laboratory data improved markedly. The fraction of lymphocytes increased in bronchoalveolar lavage fluid and OKT4/T8 decreased. Microscopic examination of transbronchial lung biopsy showed interstitial pneumonia. Both leukocyte migration inhibition test and sensitized hemagglutination test were positive for serrapeptase. Based on these findings, we diagnosed this case as Serrapeptase -induced pneumonitis.
The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial.
Singapore Med J. 1989 Feb;30(1):48-54.
We evaluated an anti-inflammatory enzyme drug Danzen (Serrapeptase : Takeda Chemical Industries) on 70 patients complaining of breast engorgement. Serrapeptase was noted to be superior to placebo for improvement of breast pain, breast swelling and induration and while 85.7% of the patients receiving serrapeptase had "Moderate to Marked" improvement, only 60.0% of the patients receiving placebo had a similar degree of improvement. "Marked" improvement was found in 22.9% of the treatment group and 2.9% of the placebo group. These differences were statistically significant. No adverse reactions were reported with the use of serrapeptase. Serrapeptase is a safe and effective method for the treatment of breast engorgement.
Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase
Minerva Cardioangiol. 1996 Oct;44(10):515-24.
This study was designed to compare the efficacy and safety of seaprose S and serrapeptase in the treatment of venous inflammatory disease. Seaprose S efficacy was assessed as good or excellent in 85% of the cases, compared with 65% for serrapeptase. Seaprose S caused no adverse reactions. During serrapeptase treatment one patient reported diarrhea, requiring temporary dosage reduction and specific treatment. It can thus be confirmed that seaprose S was effective and well tolerated in patients with inflammatory venous diseases.
A case of serratiopeptidase-induced subepidermal bullous dermatosis.
Br J Dermatol. 1999 Dec;141(6):1139-40. No abstract available.
Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase -- a prospective study
Fortschr Med. 1989 Feb 10;107(4):67-8, 71-2.
Using a quantitative standardized procedure, the swelling of the ankle produced by supination trauma was measured. In the 66 patients with fresh rupture of the lateral ligament treated surgically at our Department between December 1986 and April 1987, a prospective study of the effect of serrapeptase (Aniflazym) on post-operative swelling and pain was carried out in 3 randomized groups of patients. In the group receiving serrapeptase, the swelling had decreased by 50% on the third post-operative day, while in the other two control groups (elevation of the leg, bed rest, with and without the application of ice) no reduction in swelling had occurred at that time. Decreasing pain correlated for the most part with the reduction in swelling. Thus, the patients receiving the test substance more rapidly became pain-free than did the control groups. On the basis of these results, serrapeptase would appear to be an effective preparation for the post-operative reduction of swelling, in comparison with the classical conservative measures, for example, the application of ice.
The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus.
Arch Otorhinolaryngol. 1988;244(6):355-9.
We have evaluated the effect of serrapeptase, a proteolytic enzyme, on the elasticity and viscosity of the nasal mucus in adult patients with chronic sinusitis. Serrapeptase was administered in a dose of 30 mg/day orally for 4 weeks. Nasal mucus was collected from the nasal cavities of each patient before (week 0) and 4 weeks after the start of the medication (week 4). The storage modulus (G') and the dynamic viscosity (eta') of each specimen of nasal mucus were determined. The dynamic viscosity of the mucus at week 4 was significantly lower than that at week 0 (at frequencies of 5, 10 and 20 Hz). No significant differences were observed in the storage modulus (G') between the mucus at week 0 and week 4. Serrapeptase reduced the viscosity but not the elasticity of the nasal mucus. Serratiopeptidase and mucus.
A multi-centre, double-blind study of Serratiopeptidase versus placebo in post-antrotomy buccal swelling.
A multi-centre, double-blind, placebo-controlled trial was carried out to investigate the clinical efficacy of the anti-inflammatory enzyme Serratiopeptidase in a total of 174 patients who underwent Caldwell-Luc antrotomy for chronic empyema. Eighty-eight patients received 10 mg Serratiopeptidase 3 times on the day before operation, once on the night of the operation and 3 times daily for 5 days after operation; the other 86 received placebo. Changes in buccal swelling after operation were observed as a parameter of the response to treatment. The degree of swelling in the Serratiopeptidase -treated patients was significantly less than that in the placebo-treated patients at every point of observation after operation up to the 5th day (p less than 0.01 to p less than 0.05). Maximal swelling throughout all the post-operative points of observation was also significantly smaller in size in the Serratiopeptidase -treated group than in the placebo-treated group. No side-effects were reported.
My summation- I think Osteo-C and Serra-kinase would go very well together in an anti-inflammation program!!!
Dirk Tanis, BA, MSci
Chief Operating Officer, Applied Nutriceuticals
Similar Forum Threads
- By ddawg91 in forum Controlled LabsReplies: 3Last Post: 02-28-2007, 05:41 PM